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ABSTRACT
The Yin Yang 1 (YY1) transcription factor is a master
regulator of development, essential for early em-
bryogenesis and adult tissues formation. YY1 is
the mammalian orthologue of Pleiohomeotic, one
of the transcription factors that binds Polycomb
DNA response elements in Drosophila melanogaster
and mediates Polycomb group proteins (PcG) re-
cruitment to DNA. Despite several publications
pointing at YY1 having a similar role in mammalians,
others showed features of YY1 that are not compat-
ible with PcG functions. Here, we show that, in
mouse Embryonic Stem (ES) cells, YY1 has
genome-wide PcG-independent activities while it is
still stably associated with the INO80 chromatin-
remodeling complex, as well as with novel RNA
helicase activities. YY1 binds chromatin in close
proximity of the transcription start site of highly ex-
pressed genes. Loss of YY1 functions preferentially
led to a down-regulation of target genes expression,
as well as to an up-regulation of several small
non-coding RNAs, suggesting a role for YY1 in
regulating small RNA biogenesis. Finally, we found
that YY1 is a novel player of Myc-related transcrip-
tion factors and that its coordinated binding at pro-
moters potentiates gene expression, proposing YY1
as an active component of the Myc transcription
network that links ES to cancer cells.
INTRODUCTION
Yin Yang 1 (YY1) is a DNA binding transcription factor
discovered 20 years ago as the main binding factor,
induced by the adenoviral protein E1, of the adeno
associated virus (AAV) promoter region and takes its
name from the dual activity of the AAV promoter (1).
YY1 is also the mammalian orthologue of pleiohomeotic
(pho), one of the DNA binding transcription factors that
mediate Polycomb Group (PcG) proteins binding at the
Polycomb Response Elements (PRE) of the Drosophila
melanogaster genome (2).
PcG proteins have a key role in early embryogenesis.
They are master regulators of organism development that
control cell fate by maintaining repression of their target
genes, in part through their ability to modify histone
proteins within the surroundings of their binding sites
(3). Until now, very few DNA binding factors have been
described to have the ability to recruit PcG proteins to
speciﬁc chromatin sites and YY1 is one of the best candi-
dates (3). In fact, similar to PcG proteins, YY1 activity
results essential for mammalian development, as YY1-null
embryos die at the peri-implantation stages of embryogen-
esis (4). YY1 activity is necessary also for adult tissue
development: for instance, oligodendrocytes-speciﬁc de-
pletion of YY1 causes serious neural defects, mainly
due to lack of global nerves myelination (5). Moreover,
reduced YY1 expression in heterozygous knock out (KO)
mice induces serious growth retardation, proliferative and
neurological defects (6). Altogether, these data show the
critical role of YY1 in regulating several developmental
processes and highlights its similarities with PcG activities.
Several reports proposed YY1 as a potential recruiting
factor for Polycomb activities in mammalian cells. For
example, YY1 was shown to directly interact with the
Polycomb Repressive Complex 2 (PRC2) subunit Eed in
Burkitt’s lymphoma cells (7), to mediate PcG recruitment
during myoblasts differentiation (8) and during muscles
regeneration from satellite stem cells (9). Moreover, YY1
binding sites were identiﬁed into a putative PRE element
isolated in mammalian cells and it was shown that, when
the binding sites are mutated, PRE responsiveness is
affected (10). Finally, recent data on X-chromosome in-
activation proposed YY1 as a DNA–RNA binding factor
that links PcG-Xist to the inactive X-chromosome (11).
Despite these observations, several data pointed at YY1
having PcG-independent functions. YY1 was shown to
interact to with the INO80 complex in cancer cell lines
and proposed to have a positive effect on Cdc6 expression
(12,13). Similarly, YY1 role in nerve myelination was
linked to direct YY1 binding at the Egr2 promoter and
to activation of Egr2 expression in Schwann cells (14). In
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other transcription factors often linked with transcription-
al activation (6). In addition, YY1 was reported to control
p53 levels in a DNA independent manner (15) and to bind
the cruciform structure of Holliday junctions, suggesting a
role in DNA repair via homologous recombination that is
consistent with the genomic instability observed in YY1
deﬁcient ﬁbroblasts (13). Many of these studies are based
on in vitro or non-physiological observations, often based
on experiments made on single genes without determining
a direct YY1 association. Thus, these data do not com-
pletely clarify YY1 functions and particularly do not fully
address the real transcriptional nature of YY1. We there-
fore believe that a detailed analysis of YY1 activity in a
biologically relevant system is needed to deﬁne YY1 func-
tions at a genome-wide level. Due to YY1 essential role in
early embryogenesis (4) and the high degree in similarities
with the phenotypes observed in mutant mice for different
PcG proteins (4,16–19), we decided to characterize YY1
functions in mouse embryonic stem (ES) cells.
ES cells are the tissue culture adaptation of the cells that
form blastocyst’s inner cell mass (20). Mouse ES cells can
be expanded through an active BMP and STAT3 signaling
that maintains ES pluripotent state by preserving their po-
tential to give rise to all cells of an adult organism (20).
Such signaling stimulates the activity of several transcrip-
tion factors that are required for their maintenance and
differentiation (21). The same transcription factors are
also actively involved in the reprogramming of committed
cells to a pluripotent ES-like state (22), highlighting how
the activity of these proteins is essential for ES cell
identity. Kim and colleagues (23) recently dissected such
transcriptional network and identiﬁed three distinct
transcription modules: a PcG-module, strictly linked to
transcriptional repression; a core-module, made of tran-
scription factors that directly respond to the BMP-STAT
signaling pathway (Oct4-Nanog-Sox2); and a Myc
module, made of transcription factors such as c-Myc,
n-Myc, E2fs and Zfx. In this work, the authors showed
that the Myc-module, but not the core module, is respon-
sible for the previously identiﬁed ESC-like transcriptional
features of cancer cells. Moreover, they proposed that
high activity of the ES Myc-module predicts a poor
outcome of different kind of human tumors. Consistent
with this, Myc, like PcG proteins and YY1, is frequently
over-expressed in cancers and several studies demon-
strated direct oncogenic effects in mediating normal cell
transformation and tumor development (6,24,25).
In the present study, we show at a genome-wide
level that YY1 exerts PcG-independent functions in
ES cells. Like in cancer cells, YY1 is associated with all
components of the INO80 chromatin-remodeling complex,
as well as to newly identiﬁed partners with RNA helicase
activity. YY1 is preferentially associated with hyper-
acetylated promoters with high transcriptional activity.
Loss of YY1 functions in ES cells predominantly dimin-
ished mRNAs expression while increased the expression
levels of small non-coding RNAs such as small nuclear,
nucleolar and micro RNAs. In addition, we identiﬁed
components of the Myc transcription module as potential
cooperating factors at YY1 sites and demonstrated that
YY1 binding is prevalently associated with promoters
co-occupied by other transcription factors such as
c-Myc, n-Myc, Zfx and E2f1 at a genome-wide level.
Finally, we show that a coordinated occupancy of YY1
with the Myc transcription module correlates with an
increased expression of target genes proposing YY1 as a
partner of the Myc network.
MATERIALS AND METHODS
Cell lines generation, manipulation and culturing
All ES cell lines were grown on 0.1% gelatinized tissue
culture dishes in DMEM supplemented with 15% Serum
(Euroclone), Leukemia Inhibitory Factor (produced in
house), Penicillin-Streptomycin (Gibco), non-essential
aminoacids (Gibco), Na-Pyruvate (Gibco). BirA express-
ing ES cell clones were generated from an ES cell line
described elsewhere (26) by removing the puromycin se-
lection cassette used for targeting purposes by transient
CRE recombinase expression. The expression constructs
for Fbio-Ezh2 and Fbio-YY1 were generated by LR re-
combination of the YY1 and EZH2 coding sequences
from a pCR8 Gateway entry vector into a pCAG-Flag-
Avi-ires-Puromycin Gateway compatible destination
vector using LR recombinase (Invitrogen). Stable cell
lines were obtained by transient transfection of FBio
empty, YY1 and Ezh2 expression constructs in BirA-ES
cells using Lipofectamine 2000 (Invitrogen) and stable se-
lection with 2mg/ml of puromycin. RNA interference
(RNAi) experiments were carried out by transfecting
short interfering RNA (siRNA) oligos speciﬁc for YY1
(Sigma-Aldrich SASI_Mm01 00125709) or with a
control-scrambled (SCR) sequence (Sigma-Aldrich
SIC001) using Lipofectamine 2000 at a concentration of
50nM. Cells were harvested 48hours post-transfection
and RNA isolated by TRIzol (Invitrogen) extraction.
Stable shRNA knock down was obtained with ES cell
transduction with viral particles produced with the
LKO.1 vectors TRCN0000054556 (shYY1) and SHC202
(shSCR) purchased from Sigma-Aldrich.
Antibodies
Western blot analyses were performed using antibodies
against: YY1 (Santa Cruz, cat. sc-281); Suz12 (Santa
Cruz, Cat. sc-46264), Actr8 (Sigma-Aldrich, Cat.A2107),
Ddx5 (Abcam, Cat. ab10261), Ddx3x (Millipore, Cat.
#09-860), Vinculin (Sigma-Aldrich, Cat. V9131), HA
(Santa Cruz, Cat. sc-805), Oct4 (Abcam, Cat. ab19857),
b-Tubulin (Santa Cruz, Cat. sc-9104), Biotin (Pierce, Cat.
31852). Ezh2 and Eed were described elsewere (18).
Ruvbl2 was also previously described (27).
Immunoprecipitation and Chromatin-Immunopre-
cipitation (ChIP) analyses were carried out using anti-
bodies against: YY1 (Santa Cruz, Cat. sc-281), Suz12
(Cell Signaling, Cat. 3737), cMyc (N-262) (Santa Cruz,
Cat. sc-764) and E2f1 (C-20) (Santa Cruz, Cat. sc-193).
Rabbit IgG (Sigma, Cat. I5006) were used as negative
control.
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spectrometry analysis
All protein puriﬁcations were carried out on ES cell nuclei
prepared by 20min swelling in nuclear prep buffer (10mM
Tris, 100mM NaCl, 2mM MgCl2, 0.3 M Sucrose, 0.25 %
v/v Igepal) at 4C. Nuclei were lysed in high salt buffer
(50mM Tris–HCl pH 7.5, 300mM NaCl, 10% glycerol,
0.25% Igepal) with fresh addition of a protease inhibitor
cocktail (Roche). Direct streptavidin puriﬁcations were
carried out by over-night (ON) incubation of 25mlo f
streptavidin magnetic beads (Invitrogen, Cat. 656-01) for
each milligram of protein extract. The tandem afﬁnity
puriﬁcations were performed by incubating 20mg of
nuclear protein extract with 200ml of packed anti-Flag
agarose beads (Sigma, Cat. A2220) ON at 4Co na
rotating platform. Beads were washed six times in
minimum 10 beads volumes of high salt buffer at 4C
and protein complexes eluted for 30min with 0.5mg/ml
of ﬂag peptide (DYKDDDDK) in high salt buffer at 20C
four times. Eluates were pulled and further precipitated
with 100ml of streptavidin magnetic beads (Invitrogen
cat. 656-01) ON at 4C. Streptavidin beads were washed
six times as before at 4C and protein complexes eluted
with Laemli sample buffer (Invitrogen).
Gel electrophoresis and in-gel digestion
Proteins from both FBio-YY1 and FBio empty vector
control puriﬁcation were separated by 1D SDS–PAGE,
using 4–12% NuPAGE Novex Bis–Tris gels
(Invitrogen) and NuPAGE MES SDS running buffer
(Invitrogen) according to manufacturer’s instructions.
The gel was stained with coomassie Blue using Colloidal
Blue Staining Kit (Invitrogen). Samples were digested with
trypsin (Promega). Brieﬂy, the gel bands were cut and then
washed four times with 50mM ammonium bicarbonate,
50% ethanol and incubated with 10mM DTT in 50mM
ammonium bicarbonate for 1h at 56C for protein reduc-
tion. Alkylation step was performed incubating the sample
with 55mM iodoacetamide in 50mM ammonium bicar-
bonate for 1h at 25C in the dark. Gel pieces were washed
two times with a 50mM ammonium bicarbonate, 50%
acetonitrile solution, dehydrated with 100% ethanol and
dried in a vacuum concentrator. Digestion was performed
using 12.5ng/ml trypsin in 50mM ammonium bicarbon-
ate and incubated for 16h at 37C for protein digestion.
Supernatant was transferred to fresh tube, and the remain-
ing peptides were extracted by incubating gel pieces two
times with 30% acetonitrile (MeCN) in 3% triﬂuoroacetic
acid (TFA), followed by dehydration with 100% acetoni-
trile. The extracts were combined, reduced in volume in a
vacuum concentrator, desalted and concentrated using
RP-C18 StageTip columns and the eluted peptides used
for mass spectrometric analysis (28).
Mass spectrometry analysis
Peptide mixtures were separated by nano-LC/MSMS
using an Agilent 1100 Series nanoﬂow LC system (Agilent
Technologies), interfaced to a 7-Tesla LTQ-FT-Ultra
mass spectrometer (ThermoFisher Scientiﬁc, Bremen,
Germany). The nanoliter ﬂow LC was operated in one
column set-up with a 15-cm analytical column (75mm
inner diameter, 350mm outer diameter) packed with C18
resin (ReproSil, Pur C18AQ 3mm, Dr Maisch, Germany).
Solvent A was 0.1% FA and 5% ACN in ddH2O and
Solvent B was 95% ACN with 0.1% FA. Samples were
injected in an aqueous 0.1% TFA solution at a ﬂow rate
of 500 nl/min. Peptides were separated with a gradient of
0–40% Solvent B over 90min followed by a gradient of
40–60% for 10min and 60–80% over 5min at a ﬂow rate
of 250 nl/min. The mass spectrometer was operated in a
data-dependent mode to automatically switch between
mass spectrometry (MS) and MS/MS acquisition. In the
LTQ-FT full scan MS spectra were acquired in a range of
m/z300–1700byFTICRwithresolution r=100000atm/z
400 with a target value of 1000000. The ﬁve most intense
ions were isolated for fragmentation in the linear ion trap
using collision-induced dissociation at a target value of
5000. Singly charged precursor ions were excluded. In the
MS/MS method, a dynamic exclusion of 60s was applied
and the total cycle time was 2s. The nanoelectrospray ion
source (Proxeon, Odense, Denmark) was used with a spray
voltage of 2.4kV. No sheath and auxiliary gases were used
and capillary temperature was set to 180C. Collision gas
pressure was 1.3 millitorrs and normalized collision energy
using wide band activation mode was 35%. Ion selection
threshold was 250 counts with an activation q=0.25. The
activation time of 30ms was applied in MS2 acquisitions.
Data analysis and assigning sequences using MASCOT
The raw data from LTQ-FT Ultra were converted to mgf
ﬁles using Raw2MSM software (29). The MS/MS peak
lists were ﬁltered to contain at most six peaks per 100
Dalton intervals and searched by Daemon (version 2.2.2,
Matrix Science) against a concatenated forward and
reversed version of IPI mouse database (version 6.63)
(56073 sequences; 25214299 residues) (30). This
database was complimented with frequently observed con-
taminants (porcine trypsin and human keratins) and their
reversed sequences as well. Search parameters were: an
initial MS tolerance of 7ppm, a MS/MS mass tolerance
at 0.5 Da and full trypsin cleavage speciEcity, allowing for
up to two missed cleavages. Carbamidomethylation of
cysteine was set as a Exed modiEcation and variable modi-
ﬁcations included oxidation on methionine and acetyl-
ation on N-terminus of proteins. We accepted peptides
and proteins with a false discovery rate (FDR) of <1%,
estimated based on the number of accepted reverse
hits (31).
ChIP, bioChIP and high-throughput sequencing
ChIP assays were carried out as described previously (32).
Brieﬂy, 1% formaldehyde cross-linked chromatin was
fragmented by sonication to an average size of 200–
350bp and immunoprecipitated ON with 10mgo f
indicated antibodies. For bioChIP, 25mg of streptavidin
beads were added instead of the antibodies, following the
protocol described in (33). DNA samples were sequenced
on an Illumina Genome Analyzer II. About 36-bp short
reads were then mapped onto the mm9 release of the
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performed allowing zero to two mismatches and keeping
only the reads that align to unique positions in the
genome. The YY1 sample was compared with the
control DNA using Model-based Analysis for Chip-Seq
[MACS, (35)]. Wiggle tracks for the visualization on the
UCSC genome browser (36) were generated using MACS.
Gene Interval Notator [GIN, (37)] was then used to
annotate peaks over RefSeq mouse genes. A peak was
assigned to the transcriptional start site (TSS) of a
RefSeq gene when falling into the surrounding 4kb
(±2kb). Datasets are available for download from
NCBI’s Gene Expression Omnibus (GEO, http://www
.ncbi.nlm.nih.gov/geo) under accession number
GSE31786. Row data from previously published
ChIPseq datasets were aligned to the mm9 release follow-
ing the same criteria. Raw ChIPseq data and relative
negative controls were obtained from the following GEO
accession numbers: Jarid2 GSE19365; Ezh2 and Ring1b
GSE13084; H3K27me3 and H3K4me3 GSE12241;
H3K27AC GSE24164; cMyc,nMyc, Zfx, E2f1,
AOct4
and Sox2 GSE11431;
BOct4 and Nanog GSE11724.
De novo motif discovery
Multiple EM for Motif Elicitation [MEME, (38), version
4.4.0] was used in order to search for highly occurring
pattern in the DNA sequence underlying the putative
binding sites. The analysis was narrowed to the 50bp
(±25bp) around the peak summit. All the identiﬁed
putative binding sites were included. The analysis was
run looking on both strands for motifs with zero or one
occurrence per sequence (zoops), ranging from 6 to 16bp
in length.
Motif analysis
Position-speciﬁc weight matrices (PWMs) were collected
from the literature (39–43), and used to build a custom set
of 597 models. The YY1 putative binding site identiﬁed
through de novo motif discovery was added to this set.
For some analyses, PWMs were clustered using
BLiC (44). In this way we could reduce the complexity
of our results using a non-redundant set of 229 PWMs.
In order to identify over-represented PWMs in the YY1
putative binding sites proximal (±2.5kb from a RefSeq
TSS) regions were analyzed using Clover (45). The DNA
sequences underlying the YY1 peaks were scanned for all
the PWMs in the redundant set. Over-representation
was statistically evaluated using three independent
background sets, namely the entire chromosome 19, all
the RefSeq TSSs (±2.5kb) and all the CpG islands
annotated in the mm9 genome. A PWM was retained
only when signiﬁcantly over-represented (P0.01)
compared with all of these backgrounds. Clover is avail-
able as a standalone tool while results were parsed using a
custom Python script.
Regions bound by both c-Myc and n-Myc (now on
referred as Myc) were intersected with the YY1
proximal peaks. In this way we deﬁned three sets,
namely the YY1-bound Myc-unbound, the YY1-bound
Myc-bound and the YY1-unbound Myc-bound. For
each different class of genes, we used Pscan (46) to
detect statistically signiﬁcant over-represented PWMs
against a background dataset consisting of the three sets
pulled together. In this case, the non-redundant set was
used. In case a PWM showed P0.01 (two-tailed Welch’s
t-test) it was considered as signiﬁcantly over-represented.
The Pscan source code was modiﬁed in order to replace
the statistical evaluation step based on the z-test with a
step based on the t-test. The t-test is more suitable than the
z-test when comparing datasets with similar cardinality
(46). In order to get a graphical representation of the
results, PWMs that were found signiﬁcant in at least one
class were retained. Values were log10-transformed and
hierarchically clustered using average linkage and
Pearson correlation as distance measure. A heat map
was then drawn using this information. Pscan is available
as a standalone application, whereas the clustering and the
heatmap were performed using R.
Density proﬁle clusters were generated using
SeqMINER K-means ranked clustering REF within a
4-kb region centered on peaks’ summit. Density values
were generated using a 50-bp window.
Microarray and micro RNA analysis
RNA from two independent RNAi experiments was
hybridized independently to Mouse Gene 1.0 ST
Affymetrix Arrays. Signals were RMA normalized and
probeset with a 1.3-fold expression difference and a 95%
conﬁdence determined by ANOVA were selected for the
analyses. Datasets are available for download from
NCBI’s Gene Expression Omnibus (GEO, http://www
.ncbi.nlm.nih.gov/geo) under accession number
GSE31786.
The micro RNA (miRNA) expression was determined
using the TaqMan Rodent MicroRNA A+B Cards Set
v2.0 following manufacturer procedures. The miRNA
with a 2-fold expression difference and a 90% t-test con-
ﬁdence were selected for the analyses.
Density proﬁles clusters
Density proﬁles clusters were generated using SeqMINER
(47) K-means ranked clustering REF within a 4-kb region
centered on peaks’ summit. Density values were generated
using a 50-bp window.
Real Time quantitative PCR
RT–qPCRs were carried out using Fast Sybergreen as pre-
viously described (48). Primers used for PCRs are listed in
Supplementary Table S7.
Functional annotations
mRNA and miRNA functional annotation were
generated using Ingenuity Systems Pathway Analysis
(IPA; www.ingenuity.com). The miRNA target genes an-
notation was generated toward the validated miRNA
database of IPA.
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In order to test if YY1 shares regulatory functions with
PcG proteins, we performed ChIP analysis in E14 ES cells
using antibodies speciﬁc for mouse YY1 and a subunit of
the Polycomb Repressive Complex 2 (PRC2), Suz12. As
shown in Figure 1A, while Suz12 was strongly enriched at
known PcG binding sites, the YY1 antibody did not show
any signiﬁcant enrichment. Such result either indicate that
YY1 does not associate with these genomic sites or that
the YY1 antibody is not efﬁcient in ChIP assays. In order
to bypass these technical issues, we decided to develop a
puriﬁcation strategy that takes advantage of the in vivo
biotinylation of proteins in mouse ES cells (49). Such tech-
nique involves the constitutive expression of proteins of
interest bearing a tag (Flag-Avi; FBio) recognized by the
biotinylating enzyme BirA (Supplementary Figure S1A)
allowing in vivo biotinylation of the tagged protein (33).
Such a system has been previously used for native protein
complexes puriﬁcation, as well as for ChIP assays (49–51).
For this, we took advantage of ES cells that carry the
coding sequence of the BirA enzyme knocked-in the
Rosa26 locus that drives BirA constitutive expression
(BirA-ES) (26). As shown in Supplementary Figure S1B,
these cells constitutively express physiological levels of a
hemagglutinin-tagged version of the BirA enzyme and
normal levels of the pluripotency marker Oct4. Thus, we
generated stable cell lines expressing independently a
biotinylated (bio) form of YY1 and Ezh2 (bioYY1 and
bioEzh2), which is the catalytic subunit of the PRC2
complex (Supplementary Figure S1D and E). With these
cells, we performed a streptavidin co-precipitation experi-
ment using optimal extraction conditions (Supplementary
Figure S1C) and demonstrated that neither endogenous
YY1 nor bioYY1 co-precipitated components of the
PRC2 complex, whereas the bioEZH2 protein efﬁciently
co-precipitated endogenous core PRC2 subunits (Eed and
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Figure 1. Genome-wide localization of YY1 does not correlate with PcG proteins (A) ChIP analysis using qPCR on the indicated genomic loci using
the speciﬁed antibodies. (B) Western blot analyses using the indicated antibodies of streptavidin pull-down assays from protein extracts of ES cell
lines independently expressing bioEzh2 and bioYY1. A control ES cell line with BirA expression alone is presented as puriﬁcation control. Dotted
line denotes removal of non-relevant lanes from the original blot. (C) BioChIP analysis by qPCR on chromatin prepared from the same cell lines
presented in (B). (D) Genomic snapshots of the bioChIPseq results for YY1 and control (FBio-Crtl) BirA expressing ES cells. (E) Overlap of binding
sites between bioYY1 and the indicated ChIPseq datasets. (F and G) Overlap between target genes of the indicated ChIPseq datasets. Target genes
are deﬁned by the presence of at least one peak within ±2kb from RefSeq genes annotated TSS. P-values of the indicated overlaps are determined
by hypergeometric distribution.
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antibodies against endogenous proteins, further demon-
strating the lack of interaction between YY1 and compo-
nents of the PRC2 complex in ES cells (Supplementary
Figure S1F). Using these cell lines, we also performed
streptavidin ChIP (bioChIP) analyses at known PRC2
binding sites. Consistent with Figure 1A data, we found
that, although bioEzh2 was efﬁciently enriched at PcG
binding sites, bioYY1 was not (Figure 1C). Overall,
these data conﬁrm that YY1 does not interact with the
PRC2 complex in ES cells and does not associate with the
tested PcG binding sites.
In order to generate a genome-wide map of the bioYY1
binding proﬁle to DNA, we performed high-throughput
sequencing of the DNA enriched in bioYY1 ChIP
(ChIPseq) (Figure 1E). Enrichment analysis of the
bioYY1 ChIPseq, relative to a control BirA-ES cell line,
revealed strong enrichment sites of bioYY1 in proximity
of TSS (Figure 1D). Indeed, the overlap of all bioYY1
peaks relative to promoter regions, deﬁned as ±2kb
from TSS, showed that 80% of bioYY1 peaks were
found at genes promoters (Figure 1E). Consistent with
this, bioYY1 binding showed a similar degree of overlap
with CpG islands, a typical feature of promoter regions
(Figure 1E). Conversely, when overlapped with previously
generated ChIPseq datasets for PcG proteins in ES cells,
bioYY1 binding sites did not overlap (<5%) with compo-
nents of the PRC2 (Ezh2, Jarid2) and PRC1 (Ring1b)
complexes, as well as with regions of accumulation of re-
pressive tri-methylated (me3) histone H3 (H3) lysine (K)
27, which is the product of PRC2 enzymatic activity
(Figure 1E) (25). This result is not due to a bias of chro-
matin accessibility in bio-YY1 BirA-ES cells since both
H3K27me3 and unrelated genomic loci such as ES cells
speciﬁc enhancers or intra-genic and inter-genic regions
are efﬁciently immuno-precipitated with H3K27me and
Histone H3-speciﬁc antibodies (Supplementary Figure
S2A). These data are consistent with the observations pre-
sented in Figure 1A–C. Moreover, bioYY1 peaks strongly
overlapped (>80%) with H3K4me3 and H3K27
acetylated (ac) regions (Figure 1E): while H3K4me3 was
shown to form ‘bivalent domain’ of poised chromatin with
H3K27me3 (52), H3K27ac was demonstrated to be
mutually exclusive with H3K27me3 in ES cells (53).
Moreover, while Ring1b and Ezh2 shared nearly all
their entire set of targets, they did not signiﬁcantly
overlap bioYY1-bound promoters (Figure 1F). Consistent
with this, bioYY1 target genes were not enriched for
H3K27me3 but strongly enriched for H3K4me3,
demonstrating that bioYY1 targets are not bivalent
genes and further suggesting an association with actively
transcribed promoters (Figure 1G). A more detailed
analysis of the distribution proﬁle of bioYY1 binding
sites conﬁrmed that bioYY1 is associated preferentially
with promoter regions, to a lesser extent to intra-genic
regions and, only for a remaining 16% of binding
sites, to inter-genic regions (Figure 2A). Interestingly,
most of these intra- and inter-genic bioYY1 binding sites
did not overlap signiﬁcantly with CpG islands or with
recently identiﬁed ES enhancer regions (<10%, data not
shown) (54). Furthermore, the analysis of the density
proﬁles of the distance between the summit of peaks and
genes TSS showed that bioYY1 was strongly enriched in
close proximity of transcriptional initiation (Figure 2B), in
agreement with the examples presented in Figure 1D.
Comparison of ES cell microarray expression analyses
with bioYY1 target genes demonstrated that bioYY1 is
directly associated with the promoter of genes with high
level of transcriptional activity (Figure 2C). Indeed, func-
tional annotation of bioYY1 target genes revealed a
strong enrichment in highly expressed genes, like genes
encoding for proteins involved in RNA biogenesis,
protein synthesis and mitochondrial functions involved
particularly in embryonic development (Supplementary
Figure S3A–C). Such result is consistent with the
presence of non-bivalent H3K4me3 and with the high
level of acetylation found on H3K27 at bioYY1 binding
sites, suggesting a global activatory role of YY1 in
regulating gene transcription. Finally, sequence analysis
of bioYY1-bound genomic regions identiﬁed a motif
that perfectly matches a known YY1 DNA binding site,
strongly suggesting that bioYY1 genome-wide association
to chromatin is directly mediated by its DNA binding
activity (Figure2D).
In order to gain further insight into the functional
properties of YY1, we used bioYY1 BirA-ES cells to
identify YY1 speciﬁc interacting proteins. For this, we
performed a tandem puriﬁcation using the Flag and
biotin tag and identiﬁed by mass spectrometry (MS)
bioYY1-associated proteins in ES cells (Figure 2E). Such
analysis revealed that bioYY1 is stably associated with
several components of the INO80 chromatin-remodeling
complex in ES cells, as previously reported for cancer cells
(12,13) (Figure 2E). In addition, we identiﬁed novel inter-
acting partners of bioYY1, Ddx5 and Ddx3x, two proteins
carrying RNA helicase activity (Figure 2E). Consistent
with Figure 1 data, no peptides of PcG proteins were
found in the MS analysis. These interactions were
further validated in an independent experiment probing
the product of a streptavidin puriﬁcation with speciﬁc
antibodies against different proteins identiﬁed in the MS
analysis (Figure 2F). These ﬁndings suggest that
co-recruitment of the INO80 remodeling complex and
the RNA helicase activities could contribute to promote
active transcription from promoters bound by YY1.
In order to validate endogenous YY1 binding at target
sites and the presence of its interacting partners, we per-
formed ChIP analyses in ES cells using antibodies speciﬁc
for YY1 and Ruvbl2, a stable component of the INO80
complex. As shown in Figure 2G, both YY1 and Ruvbl2
antibodies produced a signiﬁcant enrichment over the
background signal at several gene promoters, validating
YY1 binding at the sites identiﬁed by the bioChIPseq
analysis and demonstrating the co-recruitment of the
INO80 complex at the same genomic regions.
To gain further insights into the role of YY1 in tran-
scriptional regulation, we developed an efﬁcient siRNA
mediated down-regulation of YY1 expression in mouse
ES cells (Figure 2H). Using total RNA extracted from
two independent RNAi experiments (Figure 2H),
we determined, by means of Affymetrix microarrays,
global gene expression changes upon acute YY1
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were differentially expressed, with a 95% conﬁdence,
between YY1 and SCR control siRNA-treated ES cells
(Supplementary Table S2). Importantly, 30% of the
regulated genes present YY1 binding at their TSS. Such
number is signiﬁcantly higher than expected (chi-squared
P<2
16) and strongly suggests a direct activity of YY1 in
controlling the expression of its target genes (Figure 2I).
Consistent with this, qRT–PCR analysis in cells treated
with YY1-speciﬁc siRNA or shRNA targeting sequences
validated the microarray results (Supplementary Figure
S2B). Expression of YY1 target genes was preferentially
diminished upon YY1 depletion, in agreement with an
activatory role for YY1 (Figure 2I). Nevertheless,
several transcripts were also up-regulated, suggesting
potential opposing functions for YY1 in transcrip-
tional control (Figure 2I). Interestingly, the most
up-regulated transcripts in YY1 depleted ES cells are
nuclear and nucleolar small non-coding RNAs
(sncRNA) (Supplementary Table S3). A more detailed
analysis of the whole microarray data identiﬁed 22
RNA transcripts that were differentially regulated in ab-
sence of YY1 (Figure 3A). Nearly all these RNAs (86%)
were up-regulated upon YY1 depletion (Figure 3A).
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Figure 2. YY1 complex directly regulates active gene expression. (A) Distribution of bioYY1 binding sites relative to the gene bodies of RefSeq
annotated transcripts. (B) Density proﬁle of bioYY1 binding sites relative to TSS. All binding sites within ±10kb are included in the analysis. TSS
distance is measured as the relative base pair distance to peaks’ summits. A close up image of a ±500bp TSS density proﬁle is also presented with an
identical band with (10bp). (C) Annotation of gene expression levels between bioYY1 target and non-target genes. P-values are determined by
Wilcoxon test. (D) MEME motif prediction of DNA sequences enriched in bioYY1 ChIPseq. YY1 Transfac matrix is presented for comparison.
(E) Silver staining of the isolated proteins with a Flag-Streptavidin tandem puriﬁcation using protein extracts of FBio-YY1 expressing ES cells (left).
A puriﬁcation using BirA expressing ES cells is presented as negative control. A summary table of the mass spectrometry results is presented on the
right. Protein Abundance Index (PAI) is indicated as measure of puriﬁcation efﬁciency. (F) Western blot analyses of streptavidin-puriﬁed proteins
from nuclear extracts of the indicated ES cell lines using the speciﬁed antibodies. Input lanes correspond to 2% of extract used in IPs (G) ChIP
analysis of E14 ES cells using the indicated antibodies on the speciﬁed genes TSS. (H) Western blot analysis of ES cell extracts independently
transfected with YY1-speciﬁc or scrambled (SCR) control siRNA oligos. Vinculin is presented as loading control. (I) Distribution of bioYY1 binding
at the promoters of differentially expressed genes in YY1 siRNA-treated ES cells. P-values are determined with a chi-square test. Stacked columns
show the relative distribution of up-regulated (Up) or down-regulated (Down) bioYY1 target genes.
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(chi-squared P<0.001), strongly suggesting that YY1
could play a negative role in these sncRNA biogenesis.
Since most of these sncRNAs are localized within
intra-genic regions and are generated by either independ-
ent transcription units or through splicing of longer tran-
scripts (55), we believed that our direct bioYY1 target
annotation might have missed out most of this RNA
species. Thus, we manually annotated transcript position
of the 22 sncRNAs found in our expression analysis and
established that most of the regulated sncRNAs mapped
within longer transcripts or in close proximity of a TSS
(Figure 3B). Importantly, more than 60% of sncRNAs
presented bioYY1 binding at the promoter of their
associated transcripts (Figure 3C). Intriguingly, although
sncRNA expression increased upon YY1 depletion, whole
transcript expression was unaffected, suggesting a
transcriptional independent role of YY1 in regulating
sncRNA levels.
To gain further insights for this observation, we decided
to look at the expression levels of another class of
sncRNAs, mature miRNAs. Using Applied Biosystem
TaqMan technology, we measured the expression of 752
mature miRNA species present in the mouse genome in
two independent experiments. Such analyses identiﬁed 78
miRNAs that were differentially expressed upon YY1
knock down of which more than 70% resulted
up-regulated upon YY1 RNAi, further validating our
previous observations (Figure 3D and Supplementary
Table S4). Functional analysis identiﬁed several mRNA
transcripts that had been previously validated to be
targeted by these miRNAs (summary list shown in
Figure 3E and whole list in Supplementary Table S5),
highlighting a signiﬁcant functional enrichment in cell
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Figure 3. YY1 negatively regulates sncRNAs intra-cellular levels. (A) Distribution of the differentially expressed coding RNAs (cRNA) and small
non-coding RNAs (sncRNA) present on the Mouse Gene 1.0 ST Affymetrix Array (center column). Differential distributions of up-regulated (Up) or
down-regulated (Down) RNA classes are presented in the left and right columns. P-value is determined by chi-square test. (B) Heat map of the fold
change expression values of the indicated sncRNAs and their annotated transcripts in YY1 RNAi-treated ES cells. Linear fold changes are also
indicated within the heat map boxes. Left boxes indicate the presence of bioYY1 binding and its relative position with respect to transcripts TSS. The
bioYY1 target sncRNAs are highlighted in green. YY1 binding intensity is deﬁned using peaks P-value: low >10–40; mediun <10–40 and >10–70;
High <10–70. (C) Genomic snapshots of the bioChIPseq results for YY1 and control (FBio-Crtl) at the indicated genomic loci. (D) Distribution of
regulated miRNAs upon YY1 down-regulation. Stacked columns show the relative distribution of up-regulated (Up) or down-regulated (Down)
miRNAs. (E) Summary of the number of validated target mRNAs of the indicated miRNAs identiﬁed in (D). (F) Functional annotation of miRNA
targets shown in Figure 3E using miRNAs Ingenuity Systems Pathway Analysis. Top scoring pathways are highlighted in red.
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implications with diseases such as cancer and genetic dis-
orders (Figure 3F). Overall, these data show that YY1 has
a direct positive action on genes expression but it acts
negatively on the accumulation of sncRNAs in ES cells.
These data exclude a functional interaction between
YY1 and PcG proteins and put forward YY1 as a
positive regulator of gene expression in ES cells. Thus,
to gain further insights on YY1 transcriptional activities,
we scanned the bioYY1-bound genomic regions looking
for the enrichment of known protein–DNA binding
motifs. Such analysis identiﬁed several DNA elements
enriched in proximity of bioYY1 binding sites; in particu-
lar, we found an evident over-representation of ETS tran-
scription factors (Figure 4A). In addition, one of the DNA
motifs with the highest score in the analysis was the DNA
binding site of Zfx (Figure 4A). Zfx is a transcription
factor that plays an important role in ES cell self-renewal
(56) characterized as part of the Myc module of transcrip-
tion factors (23,57). To investigate a potential overlap
between Zfx and YY1, we analyzed the distribution of
bioYY1 and Zfx ChIPseq signals across their binding
sites and found that a large part of bioYY1-bound
regions were also occupied by Zfx (70%) (Figure 4B).
The density proﬁles of both transcription factors ChIPseq
reads displayed a very similar distribution, demonstrating
that regions of association were in proximity with each
other and validate the data of the DNA motif analysis
(Figure 4A). Analysis of bioYY1 and Zfx direct target
genes further conﬁrmed this result, showing a highly
signiﬁcant overlap between bioYY1 and Zfx targets
(Figure 4C). Examples of bioYY1 and Zfx binding
proﬁles at target sites are presented in Figure 4D.
Interestingly, two subunits of the INO80 complex that
co-puriﬁed with bioYY1, Ruvbl1 and Ruvbl2, were also
shown to stably interact with a component of the
Myc-Max complex, Dmap1 (Figure2 E and F) (23).
Moreover, previous reports proposed a connection
between YY1 and Myc activities in deﬁned conditions
(58–60) that, together with the high degree of overlap
between Zfx and bioYY1 genomic association (Figure
4A–C), could suggest a functional overlap between YY1
and Myc functions. To test this, we analyzed the
genome-wide binding proﬁle of Myc transcription
factors relative to bioYY1 binding. The density proﬁles
of bioYY1 together with c-Myc and n-Myc ChIPseq
signals showed a large degree of overlap. Similar to Zfx,
both n-Myc and c-Myc bind in proximity of bioYY1 and
deﬁne different clusters of binding regions either
co-occupied by Myc and YY1 or by the proteins alone
(Figure 4E). Examples of the binding proﬁles of these
regions are shown in Figure 4F. Similarly for Zfx,
analysis of Myc and bioYY1 co-occupancy at target
genes revealed a large degree of overlap between
bioYY1- and Myc-bound promoters (Figure 4G).
Importantly, the largest group of overlapping genes is sim-
ultaneously bound by bioYY1, c-Myc and n-Myc (Figure
4H). YY1 and Myc co-occupancy was further validated at
endogenous level in both wild-type and BirA-ES cells at
several YY1 target genes (Supplementary Figure S4A–C).
Consistent with the lack of interaction between Myc and
YY1 observed in the MS analyses, loss of YY1 expression
did not alter Myc binding from co-occupied promoters
(Supplementary Figure S5A).
The discovery of YY1 and Myc co-occupancy induced
us to explore the properties of Myc-bound YY1 pro-
moters. We carried out a DNA binding sites prediction
of the promoter regions that are co-occupied by bioYY1
and Myc proteins relative to promoters that present
the binding of the two transcription factors alone.
Such analysis identiﬁed three different clusters of signiﬁ-
cantly enriched DNA binding motifs. Among the DNA
binding motifs enriched in the YY1–Myc cluster, together
with previously identiﬁed Smad and Elk binding sites
(Figure 4A), we found that sites for different E2f tran-
scription factors were also over represented in this group
(Figure 5A). To extend these ﬁndings, we carried out an
additional analysis that scanned for DNA binding motifs
preferentially associated with promoters co-occupied by
Myc and bioYY1 relative to the ones excluded from
Myc binding. Such analysis identiﬁed, together with the
Myc DNA binding site (E-BOX, green box), binding sites
for Zfp161, Gmeb1 and different E2f proteins (sky blue
boxes) (Figure 5B). In contrast, non-Myc YY1 targets
(that represent the smaller fraction of bioYY1 target pro-
moters) were strongly enriched of A-/T-rich DNA binding
motifs of which binding sites for homeobox related tran-
scription factors (yellow boxes) were extensively repre-
sented (Figure 5B). The speciﬁcity of this result is
further supported by the preferential association of
bioYY1 at CG rich promoters (Figure 2E) and suggests
a potential Myc-independent cooperation between homeo-
box factors and YY1 on a speciﬁc set of target genes.
Since E2f factors were previously characterized to be
part of the Myc transcription module in ES cells (23,57),
since E2f activity was linked to YY1 (61) and since E2f
binding sites were always enriched in our DNA motif dis-
covery analyses, we extended our genome-wide analysis to
E2f1. Analysis of E2f1 ChIPseq data from ES cells
revealed an extensive overlap with bioYY1 and Myc
binding sites (Figure 5C). Examples of binding proﬁles
for these data are presented in Figure 5D and validations
of endogenous YY1, c-Myc and E2f1 co-occupancy at
target sites are shown in Supplementary Figures S4A–C
and S5A. All together, these ﬁndings strongly suggest an
extensive cooperation between YY1 and transcription
factors previously characterized within the Myc transcrip-
tional module. An overall analysis of these data is
summarized in Figure 6A and shows the existence of dif-
ferent clusters of genomic loci characterized by different
combinations of occupancy for these ﬁve transcription
factors. Examples of the binding proﬁles at target genes
by the different transcription factors are presented in
Figure 6B. Importantly, the group co-occupied by all tran-
scription factors represents the largest group of bioYY1
targets (Figure 6C and Supplementary Table S6). Such
result is signiﬁcantly different from expected and
supports a transcriptional cooperation between YY1 and
Myc related transcription. To test this, we generated a
correlation map of the ChIPseq binding proﬁles between
bioYY1, the components of the core pluripotency module
(Oct4, Nanog and Sox2) and of Myc module (c-Myc,
Nucleic Acids Research,2012, Vol.40, No. 8 3411n-Myc, Zfx and E2f1) (Figure 6D). Such analyses clearly
demonstrate that bioYY1 binding has a strong correlation
with components of the Myc module but do not correlate
in binding with core pluripotency factors, indicating that
YY1 is part of the Myc-related transcription network.
In order to correlate transcription factors co-occupancy
at YY1-bound promoters with genes transcriptional
activity, we compare microarray expression data from
ES cells with the different classes of bioYY1 target
genes. From this analysis, we concluded that cumulative
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Figure 4. YY1 binding sites overlap with Zfx and Myc occupancy. (A) Result of Clover analysis on bioYY1 target promoters. Only the motifs with a
score >50 are presented in the table. P-values of each motif relative to the indicated reference set are presented in addition to the score values.
(B) K-means clustering of reads intensities in bioYY1 and Zfx ChIPseq data on all bioYY1- and Zfx-associated genomic loci within a 4kb region
centered on peaks’ summits. (C) Overlap between the target genes of the indicated ChIPseq datasets. Target genes are deﬁned by the presence of at
least one ChIPseq peak within ±2kb from genes annotated TSS. P-values of the indicated overlaps are determined by hypergeometric distribution.
(D) Examples of the Genomic snapshots generated in bioYY1 and Zfx ChIPseq. (E) As in (B) using bioYY1, c-Myc- and n-Myc-bound genomic loci.
(F) Examples of the Genomic snapshots generated in bioYY1, c-Myc and n-Myc ChIPseq. (G) As in (C) with bioYY1, c-Myc and n-Myc target
genes. (H) Distribution of YY1 promoters association relative to c-Myc and n-Myc co-occupancy at target genes. Chi-square test determines the
P-value.
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Figure 5. YY1–Myc binding sites are enriched for E2f1 association (A) Heat map of the known DNA binding sites enriched in the different clusters
of bio YY1- and Myc-bound promoters by Pscan analysis. Double asterisks denote P<0.01. (B) As in (A) comparing bioYY1 Myc-bound and not
bound target promoters. P-values are indicated within the boxes. Myc binding sites are highlighted in green, E2F binding sites in blue, whereas
homeobox-related binding sites in yellow. Position-speciﬁc weight matrices (PWM) are shown on the left highlighting the CG rich content of Myc
related and the A/T rich content of non-Myc YY1 associated PWMs. (C) K-means clustering of reads intensities in bioYY1, c-Myc, n-Myc and E2f1
ChIPseq data on all bioYY1 c-Myc ad n-Myc associated genomic loci within a 4-kb region centered on the peaks’ summits. (D) Examples of the
genomic snapshots generated in bioYY1, c-Myc, n-Myc, E2f1 and H3K27ac ChIPseq.
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Figure 6. YY1 is part of the Myc TF module and potentiate target genes expression. (A) K-means clustering of reads intensities in the indicated
ChIPseq data on bioYY1, c-Myc, n-Myc, Zfx and E2f1 associated genomic loci within a 4-kb region centered on each peaks’ summit. (B) Examples
of the genomic snapshots generated in the indicated ChIPseq datasets. (C) Distribution of bioYY1 binding relative to c-Myc, n-Myc, Zfx and E2f1
co-occupancy at target genes. Chi-square test determines the P-value. (D) Heat map of the correlation between the genome-wide associations of the
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(continued)binding of the different transcription factors with YY1
potentiates gene expression (Figure 6E). Interestingly,
although Myc and E2f1 binding alone have a positive
transcriptional effect, Zfx does not seem to inﬂuence
gene expression signiﬁcantly. Nevertheless, cumulative
binding of all three classes of transcription factors at
bioYY1 target genes correlate with maximal transcription-
al activity (Figure 6E, boxplots). A comparative analysis
of the same classes of target genes relative to bioYY1 as-
sociation reveals that the presence of YY1 potentiates
gene expression when combined with Myc and or E2f1
and induces maximum expression level when associated
simultaneously with all the other transcription factors
(Figure 6E, bottom heat map and Supplementary Figure
S5B). Simultaneous loss of cMyc andnMyc activity
induces loss of ES cells pluripotency and activation of
differentiation programs (62). Consistent with this,
stable shRNA mediated reduction of YY1 expression
in ES cells led to an increased expression of differenti-
ation markers and defects in the activation of some
lineage-speciﬁc genes upon differentiation in embryoid
bodies (EB) (Supplementary Figure S6A and S6B).
Importantly, EBs differentiation induced a counter selec-
tion for YY1 knock down efﬁciency (Supplementary
Figure S6A) in agreement with a potential role for YY1
in regulating proper ES cell differentiation that is consist-
ent with the severe early implantation defects observed in
YY1 KO embryos. Overall, these data demonstrate a func-
tional role of YY1 in genome-wide Myc transcriptional
functions proposing a positive effect on the expression
on genes that belong to the Myc transcriptional network.
DISCUSSION
Determination of cellular fate is a complex and still poorly
understood process that is controlled at a transcriptional
level by the activity of tissue-speciﬁc transcription factors
(21). ES cells are the cell type with the highest differenti-
ation plasticity (pluripotency) that can be isolated in tissue
culture (63). Moreover, several publications have
proposed that cancer cells share speciﬁc transcriptional
features with ES cells (ESC-like signatures) (64,65). This
makes the characterization of the transcriptional mechan-
isms that control ES self-renewal and differentiation im-
portant not only to understand their identity and plasticity
but also to characterize transcriptional features shared
with cancer cells within a physiological context. In line
with this, distinct transcriptional modules have been
proposed to control ES transcription programs. This
involves the repressive PcG module, the Myc module
and the core pluripotency factors module (23). Not sur-
prisingly, all components of these networks were shown to
play important roles in controlling ES self-renewal and
differentiation capabilities (66,67). Moreover, several of
these factors are also strongly implicated in tumor devel-
opment: the best examples are represented by the frequent
activation of PcG and Myc functions (25,59).
Here, we have presented a detailed characterization of
YY1 functions in mouse ES cells. We show that YY1
does not share physical and functional properties with
PcG proteins, while it preferentially associates with the
CG-rich promoters of actively transcribed genes that cor-
respond to non-bivalent H3K4me3 enriched and H3K27
hyper-acetylated promoters. This does not exclude that
YY1 could play a role in PcG recruitment in particular
situations but our data clearly show that this activity, if
occurs, must be restricted to very deﬁned circumstances.
Consistent with this, like in cancer cells (12,13), YY1
stably associates with components of the INO80 remodel-
ing complex, as well as with newly identiﬁed RNA helicase
activities. YY1 RNAi experiments further conﬁrm these
observations showing that loss of YY1 preferentially leads
to a down-regulation of gene expression. Although, only a
minority of direct bioYY1 target genes was impaired in
expression, this suggests that YY1 binding, together with
INO80 and RNA helicase activities, facilitates gene ex-
pression in agreement with their co-occupancy at different
target promoters. This is in line with the YY1–INO80
co-occupancy observed at Cdc6 promoter in cancer cells
(12). Lack of signiﬁcant transcriptional changes in the
majority of bioYY1 target genes could be due either
to the partial knock down that we obtained with
both YY1 siRNAs (Figure 2H) or shRNAs treatment
(Supplementary Figures S2B, S5A and S6A) or by com-
pensatory effects mediated by the other transcription
factors. Moreover, YY1–INO80 interaction has been
also proposed to play a role in DNA homologous recom-
bination that occurs in case of DNA damage (13). Due to
its ability to associate directly with the DNA cruciform
structure of Holliday junctions, YY1 has been proposed to
function as a bridge for the recruitment of INO80 re-
modeling activities at damaged sites (13). Such DNA
binding activity does not seem to require YY1 DNA
binding motifs in odds with the tight association
between the ChIPseq results and the YY1 DNA binding
elements (Figure 3D). Nevertheless, the increased genomic
instability observed in hypomorphic YY1 KO mouse em-
bryonic ﬁbroblasts supports the hypothesis that YY1
could exert this function (13). However, our knock
down studies do not show any evident genomic instability
in YY1 depleted ES cells (data not shown), either because
of the transient nature of the siRNA-based experiments
we performed or because the YY1–DNA repair activities
are suppressed by the lack of cell cycle checkpoints and the
Figure 6. Continued
indicated ChIPseq dataset. Two independent Oct4 datasets are included in the analysis. The datasets references are indicated in the ‘Materials and
Methods’ section. (E) Box plots of the expression of bioYY1 target genes relative to the co-occupancy of the indicated proteins. P-value was
determined by Kruskal–Wallis test. Bottom intensity map highlights the signiﬁcance of the contribution of bioYY1 binding relative to non-YY1
binding to target gene clusters deﬁned by the co-occupancy of the indicated proteins. P-values are indicated within the boxes and are determined by
Wilcoxon test. (F) Model of YY1, Myc, Zfx and E2f1 co-occupancy at target promoters of transcribed genes. The model includes data from previous
puriﬁcations of Myc complexes from ES cells (23) and speculates on potential transcriptional and post-transcriptional activities of YY1.
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Finally, the genome-wide combination of expression and
localization analyses that we have performed allows
strengthening a direct role of YY1 to regulate its target
genes expression. Despite a signiﬁcant portion of tran-
scripts increases expression in absence of YY1 activity,
the ﬁnding that the most up-regulated transcripts belong
to classes of sncRNAs is very surprising and intriguing.
It is not clear if YY1 binding plays a role in regulating
differential transcriptional units of sncRNAs or if it plays
a role in the biogenesis of these mature RNAs. The direct
binding of YY1 to the promoters of most of these
sncRNAs associated mRNAs might suggest that either
YY1 binding suppresses the activation of alternative
sncRNA transcription units or that YY1, together with
the INO80 remodeling and the RNA helicases activities,
can have a negative effect on sncRNA processing, hence
altering their stability. It is also possible that sncRNAs
up-regulation is an indirect effect of a stress response
caused by YY1 down-regulation. However, the direct
binding of YY1 in proximity of sncRNA genomic loci
could support a direct role of YY1 in regulating their
cellular levels.
Both our ﬁnding that YY1 do not share functional
properties with PcG activities and that instead share
a global regulatory functions with the Myc-related
transcriptional network are in perfect line with other
observations. YY1 was shown to possess the ability, in
non-physiological conditions, to interact with Myc
(58,59). The lack of Myc protein in our YY1 puriﬁcation,
as well as in others performed in cancer cells (12,13)
clearly shows that, if Myc interacts physiologically with
YY1, such binding is not stable. Nevertheless, this could
be important to stabilize the genome-wide DNA mediated
co-occupancy of YY1 and Myc at their shared binding
sites. Similar to this, E2f1 was also shown to interact
in vitro with YY1 (61) but, like Myc, was not found in
the YY1 puriﬁcations. In addition, YY1 was also shown
to directly activate expression from the Myc promoter and
to increase, when overexpressed, Myc endogenous tran-
scripts (70,71). In ES cells, we do not observe binding of
YY1 at any Myc paralog promoters neither we detect sig-
niﬁcant expression changes in Myc expression
(Supplementary Table S2) suggesting that this regulatory
mechanism is not conserved in ES cells.
Our data on the transcriptional cooperation between
YY1 and the Myc module of transcription factors are in
line with previous observations. For example, YY1 was
shown to cooperate with Myc in activating Surf-1 expres-
sion (60) while it was shown to act synergistically with
E2F1 in activating the Cdc6 promoter (61). The cMyc
andnMyc KO mice are both early embryonic lethal
(72–74) (E10.5 and E11.5, respectively) (72–74) and
double Myc KO ES cells activate differentiation genes ex-
pression and loose their pluripotency (62). Similarly, re-
duction of YY1 expression induces the activation of
differentiation markers and genes related to embryonic
development. Moreover, differentiation of these cells
induced a strong counter selection for YY1 knock down
efﬁciency that is suggestive of a potential role for YY1 in
differentiation consistent with its essential role early
implantation development. Generation of inducible YY1
KO ES cells will therefore be an invaluable tool to extend
these observations. Importantly, in addition to the essen-
tial function in regulating normal development and differ-
entiation, YY1 and Myc are both activated in
NDEA-induced hepatocarcinogenesis (75), as well as in
Burkitt Lymphomas (76) and in prostate cancers (77).
Interestingly, YY1 and Zfx were identiﬁed out of six
proteins that scored in a proteomic study aimed to
identify proteins expressed in neoplastic nodes of diffuse
large B cell and Follicular lymphomas (78), two tumor
types that are frequently driven by Myc ampliﬁcations
and overexpression (24). Altogether, our data on the
global transcriptional cooperation between YY1 and the
Myc transcription network (summarized in Figure 6F)
makes a big stem in putting together little pieces of obser-
vations disperse over several years of literature and
identify a novel component of a keystone transcriptional
regulatory network of normal pluripotent and cancer cells.
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